This title appears in the Scientific Report :
2010
Please use the identifier:
http://dx.doi.org/10.1017/S0033291709992376 in citations.
Human amygdale reactivity is diminished by the beta-noradrenergic antagonist propranolol
Human amygdale reactivity is diminished by the beta-noradrenergic antagonist propranolol
Animal models of anxiety disorders emphasize the crucial role of locus ceruleus-noradrenergic (norepinephrine, NE) signaling, the basolateral amygdala (BLA) and their interactions in the expression of anxiety-like behavioral responses to stress. Despite clinical evidence for the efficacy of a β-nora...
Saved in:
Personal Name(s): | Hurlemann, R. |
---|---|
Walter, H. / Rehme, A.K. / Kukolja, J. / Santoro, S.C. / Schmidt, C. / Schnell, K. / Musshoff, F. / Keysers, C. / Maier, W. / Kendrick, K.M. / Onur, O.A. | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | Psychological medicine, 40 (2010) S. 1839 - 1848 |
Imprint: |
Cambridge
Cambridge Univ. Press
2010
|
Physical Description: |
1839 - 1848 |
PubMed ID: |
20102667 |
DOI: |
10.1017/S0033291709992376 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity Funktion und Dysfunktion des Nervensystems |
Series Title: |
Psychological Medicine
40 |
Subject (ZB): | |
Publikationsportal JuSER |
LEADER | 06564nam a2201141 a 4500 | ||
---|---|---|---|
001 | 14961 | ||
005 | 20210129210619.0 | ||
980 | |a VDB | ||
980 | |a ConvertedRecord | ||
980 | |a journal | ||
980 | |a I:(DE-Juel1)INM-3-20090406 | ||
980 | |a UNRESTRICTED | ||
700 | 1 | |0 P:(DE-HGF)0 |a Walter, H. |b 1 | |
700 | 1 | |0 P:(DE-HGF)0 |a Rehme, A.K. |b 2 | |
700 | 1 | |0 P:(DE-HGF)0 |a Kukolja, J. |b 3 | |
700 | 1 | |0 P:(DE-HGF)0 |a Santoro, S.C. |b 4 | |
700 | 1 | |0 P:(DE-HGF)0 |a Schmidt, C. |b 5 | |
700 | 1 | |0 P:(DE-HGF)0 |a Schnell, K. |b 6 | |
700 | 1 | |0 P:(DE-HGF)0 |a Musshoff, F. |b 7 | |
700 | 1 | |0 P:(DE-HGF)0 |a Keysers, C. |b 8 | |
700 | 1 | |0 P:(DE-HGF)0 |a Maier, W. |b 9 | |
700 | 1 | |0 P:(DE-HGF)0 |a Kendrick, K.M. |b 10 | |
700 | 1 | |0 P:(DE-Juel1)131736 |a Onur, O.A. |b 11 |u FZJ | |
856 | 7 | |u http://dx.doi.org/10.1017/S0033291709992376 | |
909 | C | O | |o oai:juser.fz-juelich.de:14961 |p VDB |
970 | |a VDB:(DE-Juel1)127488 | ||
520 | |a Animal models of anxiety disorders emphasize the crucial role of locus ceruleus-noradrenergic (norepinephrine, NE) signaling, the basolateral amygdala (BLA) and their interactions in the expression of anxiety-like behavioral responses to stress. Despite clinical evidence for the efficacy of a β-noradrenergic receptor blockade with propranolol in the alleviation of anxiety symptoms and the secondary prevention of post traumatic stress disorder, preclinical evidence for a β-noradrenergic modulation of BLA activity in humans is missing.We combined functional magnetic resonance imaging in healthy volunteers with probabilistic mapping of intra-amygdalar responses to fearful, neutral and happy facial expressions to test the hypothesis that a β-noradrenergic receptor blockade with propranolol would inactivate the BLA.Consistent with our a priori hypothesis, propranolol diminished BLA responses to facial expressions, independent of their emotional valence. The absence of activity changes in probabilistically defined visual control regions underscores the specific action of propranolol in the BLA.Our findings provide the missing link between the anxiolytic potential of propranolol and the biological basis of β-noradrenergic activation in the human BLA as a key target for the pharmacological inhibition of anxiety neurocircuitry. Moreover, our findings add to emerging evidence that NE modulates both the reactivity (sensitivity) and the operating characteristics (specificity) of the BLA via β-noradrenergic receptors. | ||
653 | 2 | 0 | |2 Author |a Amygdala |
653 | 2 | 0 | |2 Author |a anxiety |
653 | 2 | 0 | |2 Author |a basolateral amygdala |
653 | 2 | 0 | |2 Author |a face |
653 | 2 | 0 | |2 Author |a fear |
653 | 2 | 0 | |2 Author |a fMRI |
653 | 2 | 0 | |2 Author |a noradrenaline |
653 | 2 | 0 | |2 Author |a propranolol |
650 | 2 | |2 MeSH |a Adrenergic beta-Antagonists: pharmacology | |
650 | 2 | |2 MeSH |a Adult | |
650 | 2 | |2 MeSH |a Amygdala: drug effects | |
650 | 2 | |2 MeSH |a Amygdala: physiology | |
650 | 2 | |2 MeSH |a Anxiety: drug therapy | |
650 | 2 | |2 MeSH |a Anxiety: physiopathology | |
650 | 2 | |2 MeSH |a Double-Blind Method | |
650 | 2 | |2 MeSH |a Facial Expression | |
650 | 2 | |2 MeSH |a Fear: drug effects | |
650 | 2 | |2 MeSH |a Fear: physiology | |
650 | 2 | |2 MeSH |a Female | |
650 | 2 | |2 MeSH |a Happiness | |
650 | 2 | |2 MeSH |a Humans | |
650 | 2 | |2 MeSH |a Magnetic Resonance Imaging | |
650 | 2 | |2 MeSH |a Male | |
650 | 2 | |2 MeSH |a Propranolol: pharmacology | |
650 | 2 | |2 MeSH |a Young Adult | |
650 | 7 | |0 0 |2 NLM Chemicals |a Adrenergic beta-Antagonists | |
650 | 7 | |0 525-66-6 |2 NLM Chemicals |a Propranolol | |
650 | 7 | |2 WoSType |a J | |
915 | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed | ||
914 | 1 | |y 2010 | |
500 | |a This work was supported by a German Federal Ministry of Education and Research grant (01GW0671) (to R.H.), a German Research Foundation grant (HU1302/2-1) (to R. H.), a Starting Independent Researcher Grant jointly provided by the Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia and the University of Bonn (to R.H.), an NWO Vidi grant (to C.K.) and a European Commission Marie Curie Excellence grant (to C.K.). The authors thank G.R. Fink for providing resources and expertise, and A. Patin for reading the manuscript. | ||
773 | |0 PERI:(DE-600)1470300-2 |a 10.1017/S0033291709992376 |g Vol. 40, p. 1839 - 1848 |p 1839 - 1848 |q 40<1839 - 1848 |t Psychological medicine |v 40 |x 0033-2917 |y 2010 | ||
300 | |a 1839 - 1848 | ||
082 | |a 610 | ||
440 | 0 | |0 15421 |a Psychological Medicine |v 40 |x 0033-2917 |y 11 | |
588 | |a Dataset connected to Web of Science, Pubmed | ||
084 | |2 WoS |a Psychology, Clinical | ||
084 | |2 WoS |a Psychiatry | ||
084 | |2 WoS |a Psychology | ||
245 | |a Human amygdale reactivity is diminished by the beta-noradrenergic antagonist propranolol | ||
024 | 7 | |2 pmid |a pmid:20102667 | |
024 | 7 | |2 DOI |a 10.1017/S0033291709992376 | |
024 | 7 | |2 WOS |a WOS:000283799300011 | |
024 | 7 | |a altmetric:7408030 |2 altmetric | |
037 | |a PreJuSER-14961 | ||
260 | |a Cambridge |b Cambridge Univ. Press |c 2010 | ||
100 | 1 | |0 P:(DE-HGF)0 |a Hurlemann, R. |b 0 | |
041 | |a eng | ||
913 | 2 | |0 G:(DE-HGF)POF3-572 |1 G:(DE-HGF)POF3-570 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l Decoding the Human Brain |v (Dys-)function and Plasticity |x 0 | |
913 | 1 | |0 G:(DE-HGF)POF2-89572 |a DE-HGF |v (Dys-)function and Plasticity |x 1 |4 G:(DE-HGF)POF |1 G:(DE-HGF)POF3-890 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |b Programmungebundene Forschung |l ohne Programm | |
536 | |a (Dys-)function and Plasticity |0 G:(DE-HGF)POF2-89572 |c POF2-89572 |f POF II T |x 1 | ||
536 | |a Funktion und Dysfunktion des Nervensystems |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |x 0 |c FUEK409 | ||
336 | |a ARTICLE |2 BibTeX | ||
336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
336 | |a Output Types/Journal article |2 DataCite | ||
336 | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) | ||
336 | |a article |2 DRIVER | ||
336 | |a JOURNAL_ARTICLE |2 ORCID | ||
920 | |k Kognitive Neurowissenschaften; INM-3 |0 I:(DE-Juel1)INM-3-20090406 |g INM |l Kognitive Neurowissenschaften |x 0 | ||
991 | |0 P:(DE-HGF)0 |a Maier, W. |b 9 | ||
991 | |0 P:(DE-HGF)0 |a Keysers, C. |b 8 | ||
991 | |0 P:(DE-HGF)0 |a Musshoff, F. |b 7 | ||
991 | |0 P:(DE-HGF)0 |a Schnell, K. |b 6 | ||
990 | |0 P:(DE-HGF)0 |a Hurlemann, R. |b 0 | ||
991 | |a Onur, Özgür |0 P:(DE-Juel1)131736 |b 11 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Schmidt, C. |b 5 | ||
991 | |0 P:(DE-HGF)0 |a Kendrick, K.M. |b 10 | ||
991 | |0 P:(DE-HGF)0 |a Santoro, S.C. |b 4 | ||
991 | |0 P:(DE-HGF)0 |a Kukolja, J. |b 3 | ||
991 | |0 P:(DE-HGF)0 |a Rehme, A.K. |b 2 | ||
991 | |0 P:(DE-HGF)0 |a Walter, H. |b 1 |